US2010215690A1PendingUtilityA1

Circovirus sequences associated with piglet weight loss disease (pwd)

83
Assignee: WYETH CORPPriority: Dec 5, 1997Filed: Dec 11, 2009Published: Aug 26, 2010
Est. expiryDec 5, 2017(expired)· nominal 20-yr term from priority
Inventors:André JestinEmmanuel AlbinaPierre Le CannPhilippe BlanchardEvelyne HutetClaire ArnauldCatherine TruongDominique MaheRoland CarioletFrançois Madec
A61K 39/12A61K 2039/5256A61K 2039/5254C12N 7/00A61P 31/20A61K 48/00A61K 2039/55566A01K 2217/05C12N 2750/10061A61P 31/16A61K 2039/55522C12N 2750/10034G01N 33/56983A61P 31/04G01N 2469/20C12N 2750/10051A61K 2039/552C07K 14/005C12N 2710/14143A61P 31/12C07K 2319/55A61K 2039/58A61P 31/22A61K 2039/53Y10T428/13A61K 2039/525C12N 2750/10022A61K 2039/55A61P 37/02G01N 2333/01A61K 2039/5252C12N 2750/10021A61P 33/00A61K 39/00
83
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.

Claims

exact text as granted — not AI-modified
1 .- 16 . (canceled) 
     
     
         17 . A method for the treatment or prophylaxis of PCV2 infection or for the reduction of clinical symptoms caused by or associated with a PCV2 infection in animals having anti-PCV2 antibodies and/or being 1 to 22 days of age, comprising the step of administering an effective amount of a PCV2 antigen to that animal in need of such treatment. 
     
     
         18 . The method according to  claim 17 , wherein those anti-PCV2 antibodies are maternal antibodies. 
     
     
         19 . The method according to  claim 17  or  claim 18 , wherein the animals have an anti-PCV2 antibody titer of more than 1:100 in a PCV specific immunoassay. 
     
     
         20 . The method according to  claim 17 ,  claim 18 , or  claim 19 , wherein the animals have an anti-PCV2 antibody titer of more than 1:1000 in a PCV specific immunoassay. 
     
     
         21 . The method according to  claim 17 ,  claim 18 ,  claim 19 , or  claim 20 , wherein the treated animals have that anti-PCV2 antibody titre at the time the PCV2 antigen is administered. 
     
     
         22 . The method according to  claim 17 ,  claim 18 ,  claim 19 ,  claim 20 , or  claim 21 , wherein the PCV2 antigen is administered at day 7 of age or later. 
     
     
         23 . The method according to  claim 17 ,  claim 18 ,  claim 19 ,  claim 20 ,  claim 21 , or  claim 22 , wherein the PCV-2 antigen is administered at day 14 of age or later. 
     
     
         24 . The method according to  claim 17 ,  claim 18 ,  claim 19 ,  claim 20 ,  claim 21 ,  claim 22 , or  claim 23 , wherein the PCV-2 antigen is administered not later than at week 7 of age. 
     
     
         25 . The method according to  claim 17 ,  claim 18 ,  claim 19 ,  claim 20 ,  claim 21 ,  claim 22 ,  claim 23 , or  claim 24 , wherein the treatment or prophylaxis results in shortening of the viremia phase of 5 or more days as compared to animals of a non-treated control group of the same species. 
     
     
         26 . The method according to  claim 17 ,  claim 18 ,  claim 19 ,  claim 20 ,  claim 21 ,  claim 22 ,  claim 23 ,  claim 24 , or  claim 25 , wherein said PCV2 antigen is a polypeptide having at least 80% homology with ORF-2 of PCV2. 
     
     
         27 . The method according to  claim 17 ,  claim 18 ,  claim 19 ,  claim 20 ,  claim 21 ,  claim 22 ,  claim 23 ,  claim 24 ,  claim 25 , or  claim 26 , wherein said PCV-2 antigen is a recombinant baculovirus expressed ORF-2 of PCV2. 
     
     
         28 . The method according to  claim 17 ,  claim 18 ,  claim 19 ,  claim 20 ,  claim 21 ,  claim 22 ,  claim 23 ,  claim 24 ,  claim 25 ,  claim 26 , or  claim 27 , wherein 0.5 to 18 μg/dose of said PCV2 antigen is administered to that animal in need of such treatment. 
     
     
         29 . The method according to  claim 17 ,  claim 18 ,  claim 19 ,  claim 20 ,  claim 21 ,  claim 22 ,  claim 23 ,  claim 24 ,  claim 25 ,  claim 26 ,  claim 27 , or  claim 28 , wherein only one dose of PCV2 antigen is administered to that animal in need of such treatment. 
     
     
         30 . The method according to  claim 17 ,  claim 18 ,  claim 19 ,  claim 20 ,  claim 21 ,  claim 22 ,  claim 23 ,  claim 24 ,  claim 25 ,  claim 26 ,  claim 27 ,  claim 28 , or  claim 29 , wherein said treatment or prohylaxis of PCV2 infection results in an improvement in comparison to animals of a non-treated control group of the same species in a vaccine efficacy parameter selected from the group consisting of a reduction in the loss of weight gain, a shorter duration of viremia, an earlier end to viremia, a lower virus load, or combinations thereof. 
     
     
         31 . The method according to  claim 17 ,  claim 18 ,  claim 19 ,  claim 20 ,  claim 21 ,  claim 22 ,  claim 23 ,  claim 24 ,  claim 25 ,  claim 26 ,  claim 27 ,  claim 28 ,  claim 29 , or  claim 30 , wherein the animal is swine. 
     
     
         32 . Use of PCV2 antigen or an immunogenic composition comprising PCV2 antigen for the preparation of a medicine for the prophylaxis and treatment of porcine respiratory disease complex (PRDC) and/or any clinical sign associated with PRDC in an animal. 
     
     
         33 . The use according to  claim 32 , wherein the medicine is administered to an animal in need of such treatment in a therapeutically effective amount. 
     
     
         34 . The use according to  claim 32 , wherein the clinical sign associated with PRDC is selected from the group consisting of cough and dyspnea, slow growth, decreased feed efficiency, lethargy, anorexia, a marked increase in mortality in the middle to late phase of fattening, and combinations thereof. 
     
     
         35 . The use according to  claim 34 , wherein the cough and dyspnea are refractory to antibiotic therapy. 
     
     
         36 . The use according to  claim 32 , wherein the PRDC is associated with a PCV2 infection. 
     
     
         37 . The use according to  claim 36 , wherein the PRDC is caused by PCV2. 
     
     
         38 . The use according to  claim 37 , wherein the PRDC is further associated with and/or caused by an infection with PRRSV,  Mycoplasma hyopneumoniae, Bordetella bronchiseptica , Swine influenza virus,  Actinobacillus pleuropneumoniae, Mycoplasma hyorhinis, Streptococcus suis  and/or  Pasteurella multocida.    
     
     
         39 . The use according to  claim 32 , wherein the animal belongs to a herd that is positive for PCV2. 
     
     
         40 . The use according to  claim 32 , wherein the animal belongs to a herd that is positive for PCV2 and one or more further pathogen(s) selected from the group consisting of PRRSV,  Mycoplasma hyopneumoniae, Bordetella bronchiseptica , Swine influenza virus,  Mycoplasma hyorhinis, Streptococcus suis  and/or  Pasteurella multocida.    
     
     
         41 . The use according to  claim 32 , wherein the animal belongs to a farm that is positive for PCV2. 
     
     
         42 . The use according to  claim 32 , wherein the animal belongs to a farm that is positive for PCV2 and one or more further pathogen(s) selected from the group consisting of PRRSV,  Mycoplasma hyopneumoniae, Bordetella bronchiseptica , Swine influenza virus,  Mycoplasma hyorhinis, Streptococcus suis  and/or  Pasteurella multocida.    
     
     
         43 . The use according to  claim 32 , wherein said PCV2 antigen is a polypeptide having at least 80% homology with ORF-2 of PCV2. 
     
     
         44 . The use according to  claim 32 , wherein said PCV-2 antigen is a recombinant baculovirus expressed ORF-2 of PCV2. 
     
     
         45 . The use according to  claim 32 , wherein the animal is swine. 
     
     
         46 . A method for the prophylaxis or treatment of porcine respiratory disease complex (PRDC) and/or any clinical sign associated with PRDC in an animal, comprising the step of administering a therapeutically effective amount of PCV2 antigen or an immunogenic composition comprising a PCV2 antigen to an animal in need of such treatment. 
     
     
         47 . The method according to  claim 46 , wherein the clinical sign associated with PRDC is selected from the group consisting of cough and dyspnea, slow growth, decreased feed efficiency, lethargy, anorexia, a marked increase in mortality in the middle to late phase of fattening, and combinations thereof. 
     
     
         48 . The method according to  claim 47 , wherein the cough and dyspnea are refractory to antibiotic therapy. 
     
     
         49 . The method according to  claim 46 , wherein the PRDC is associated with a PCV2 infection. 
     
     
         50 . The method according to  claim 49 , wherein the PRDC is caused by PCV2. 
     
     
         51 . The method according to  claim 50 , wherein the PRDC is further associated with and/or caused by an infection with PRRSV,  Mycoplasma hyopneumoniae, Bordetella bronchiseptica , Swine influenza virus,  Actinobacillus pleuropneumoniae, Mycoplasma hyorhinis, Streptococcus suis  and/or  Pasteurella multocida.    
     
     
         52 . The method according to  claim 46 , wherein the animal belongs to a herd that is positive for PCV2. 
     
     
         53 . The method according to  claim 46 , wherein the animal belongs to a herd that is positive for PCV2 and one or more further pathogen(s) selected from the group consisting of PRRSV,  Mycoplasma hyopneumoniae, Bordetella bronchiseptica , Swine influenza virus,  Mycoplasma hyorhinis, Streptococcus suis  and/or  Pasteurella multocida.    
     
     
         54 . The method according to  claim 46 , wherein the animal belongs to a farm that is positive for PCV2. 
     
     
         55 . The method according to  claim 46 , wherein the animal belongs to a farm that is positive for PCV2 and one or more further pathogen(s) selected from the group consisting of PRRSV,  Mycoplasma hyopneumoniae, Bordetella bronchiseptica , Swine influenza virus,  Mycoplasma hvorhinis, Streptococcus suis  and/or  Pasteurella multocida.    
     
     
         56 . The method according to  claim 46 , wherein said PCV2 antigen is a polypeptide having at least 80% homology with ORF-2 of PCV2. 
     
     
         57 . The method according to  claim 46 , wherein said PCV-2 antigen is a recombinant baculovirus expressed ORF-2 of PCV2. 
     
     
         58 . The method according to  claim 46 , wherein the animal is swine.

Join the waitlist — get patent alerts

Track US2010215690A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.